Characterization and Management of Arrhythmic Events in Young Patients With Brugada Syndrome

Yoav Michowitz, Anat Milman, Antoine Andorin, Georgia Sarquella-Brugada, M. Cecilia Gonzalez Corcia, Jean Baptiste Gourraud, Giulio Conte, Frederic Sacher, Jimmy J.M. Juang, Sung Hwan Kim, Eran Leshem, Philippe Mabo, Pieter G. Postema, Aviram Hochstadt, Yanushi D. Wijeyeratne, Isabelle Denjoy, Carla Giustetto, Yuka Mizusawa, Zhengrong Huang, Camilla H. JespersenShingo Maeda, Yoshihide Takahashi, Tsukasa Kamakura, Takeshi Aiba, Elena Arbelo, Andrea Mazzanti, Giuseppe Allocca, Ramon Brugada, Ruben Casado-Arroyo, Jean Champagne, Silvia G. Priori, Christian Veltmann, Pietro Delise, Domenico Corrado, Josep Brugada, Kengo F. Kusano, Kenzo Hirao, Leonardo Calo, Masahiko Takagi, Jacob Tfelt-Hansen, Gan Xin Yan, Fiorenzo Gaita, Antoine Leenhardt, Elijah R. Behr, Arthur A.M. Wilde, Gi Byoung Nam, Pedro Brugada, Vincent Probst, Bernard Belhassen*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Background: Information on young patients with Brugada syndrome (BrS) and arrhythmic events (AEs) is limited. Objectives: The purpose of this study was to describe their characteristics and management as well as risk factors for AE recurrence. Methods: A total of 57 patients (age ≤20 years), all with BrS and AEs, were divided into pediatric (age ≤12 years; n = 26) and adolescents (age 13 to 20 years; n = 31). Results: Patients’ median age at time of first AE was 14 years, with a majority of males (74%), Caucasians (70%), and probands (79%) who presented as aborted cardiac arrest (84%). A significant proportion of patients (28%) exhibited fever-related AE. Family history of sudden cardiac death (SCD), prior syncope, spontaneous type 1 Brugada electrocardiogram (ECG), inducible ventricular fibrillation at electrophysiological study, and SCN5A mutations were present in 26%, 49%, 65%, 28%, and 58% of patients, respectively. The pediatric group differed from the adolescents, with a greater proportion of females, Caucasians, fever-related AEs, and spontaneous type-1 ECG. During follow-up, 68% of pediatric and 64% of adolescents had recurrent AE, with median time of 9.9 and 27.0 months, respectively. Approximately one-third of recurrent AEs occurred on quinidine therapy, and among the pediatric group, 60% of recurrent AEs were fever-related. Risk factors for recurrent AE included sinus node dysfunction, atrial arrhythmias, intraventricular conduction delay, or large S-wave on ECG lead I in the pediatric group and the presence of SCN5A mutation among adolescents. Conclusions: Young BrS patients with AE represent a very arrhythmogenic group. Current management after first arrhythmia episode is associated with high recurrence rate. Alternative therapies, besides defibrillator implantation, should be considered.

Original languageEnglish
Pages (from-to)1756-1765
Number of pages10
JournalJournal of the American College of Cardiology
Issue number14
StatePublished - 16 Apr 2019


  • Brugada syndrome
  • SCN5A mutation
  • ablation
  • adolescence
  • pediatric
  • quinidine


Dive into the research topics of 'Characterization and Management of Arrhythmic Events in Young Patients With Brugada Syndrome'. Together they form a unique fingerprint.

Cite this